In July 2026, the American Heart Association (AHA) and the American College of Cardiology (ACC) published their first joint guidelines for the cardiovascular-kidney-metabolic (CKM) syndrome. This pivotal shift emphasizes an integrated approach to heart, kidney, and metabolic health rather than simply lowering blood pressure in isolation.
SGLT2 Inhibitors and GLP-1 Agonists: Cornerstones of Therapy
The new guidelines advocate for early intervention, particularly for patients with chronic kidney disease (CKD). Central to these recommendations are SGLT2 inhibitors and GLP-1 receptor agonists. These agents not only help regulate blood sugar levels but also provide documented protection for the heart and kidneys.
Additionally, a new S3 guideline focuses on cardiovascular protection in inflammatory rheumatic diseases such as rheumatoid arthritis and lupus. Experts suggest a “treat-to-target” strategy wherein disease activity needs to be reduced consistently to mitigate cardiovascular risks. Caution is advised regarding the use of glucocorticoids and non-steroidal anti-inflammatory drugs (NSAIDs), which should be replaced with drugs that exhibit cardiovascular benefits.
Emerging Therapies for Kidney Damage
Progress is being made in nephrology, particularly in the treatment of proteinuria. Atrasentan, developed by Novartis, has recently received approval in Canada for IgA nephropathy. Additionally, the FDA has initiated an expedited process for Atacicept, which demonstrated a 42% reduction in proteinuria in a Phase 3 study compared to placebo.
Standard combination therapies, like amlodipine and valsartan, remain fundamental. However, caution is essential in cases of severe liver insufficiency or unstable heart failure post-myocardial infarction. Current research is exploring ultra-low-dose triple combinations: three drugs at half or quarter doses in one tablet may achieve target blood pressure more quickly while reducing side effects.
Addressing Inflammation as a New Target
The new AHA/ACC guidelines for CKM syndrome call for integrated treatment for heart, kidney, and metabolic health. Researchers increasingly recognize the link between inflammation and organ damage. A study in *Cardiovascular Research* identified oxalate as a trigger for IL-17A-mediated inflammation affecting both the kidneys and heart. In animal models, blocking IL-17A improved organ functionality, presenting a new avenue for potential treatments.
In clinical development, the oral NLRP3 inhibitor BGE-102 from BioAge Labs is being studied to evaluate its cardiovascular risk reduction potential. Phase 1 trials have already shown significant reductions in the inflammatory marker hsCRP, with results from current studies expected in the second half of 2026.
Catheter Gene Therapy and Lifestyle Changes: Game Changers
The German Heart Center Charité (DHZC) is working on a catheter-based perfusion system for delivering gene therapy directly to the kidneys. This method offers significantly higher vector concentrations, representing a promising approach for genetically influenced kidney diseases.
Lifestyle modifications also show significant effects. A study published in *BMJ Nutrition* demonstrated that six months of low-carb coaching led to significant reductions in weight and HbA1c values among type 2 diabetics. Isometric resistance training can lower systolic blood pressure within two weeks, while aerobic exercise can result in long-term decreases of up to 8 mmHg in systolic values.
Perioperative Management and Heat Warning
SGLT2 inhibitors and GLP-1 agonists provide proven protection for the heart and kidneys. But which patients benefit the most? Our guidelines offer a clear overview of the new recommendations to help clinicians make informed treatment decisions.
A consensus paper in the *British Journal of Anaesthesia* recommends an individualized approach to SGLT2 inhibitors prior to surgery. Depending on the risk of euglycemic ketoacidosis, these medications should be halted three to four days before major procedures.
Moreover, medical professionals are alerting us to consider environmental factors. An analysis of 1.3 million patient records revealed that not just prolonged heat, but rapid temperature increases significantly elevate the risk of acute cardiovascular events. Vulnerable patient groups require close monitoring during extreme weather conditions.
Disclaimer: Our articles do not constitute investment advice or a recommendation to buy or sell securities. Information on prices, companies, and markets is without guarantee; changes are possible at any time. Trading in stocks may result in significant losses. Our contributions are created and reviewed partly with the assistance of AI.
